Vertex Pharmaceuticals

Registered Principal Details

Business Or Interest:
Vertex is a global biotechnology company that aims to discover, develop and commercialize innovative new medicines so people with serious diseases can lead better lives.

Lobbying Interests:
Engage on access issues relating to non-opioid Pain Alternatives; access to healthcare; Awareness activities specific to Cystic Fibrosis, Sickle Cell Disease, T1D, Kidney Disease, and Pain.

CEO Name:
Reshma Kewalramani

Contact
AP
Abigail Parta
50 Northern Avenue
Boston, MA 20001
(312) 835-9997
compliance_wi_vertex@multistate.us
http://www.vrtx.com

Authorized Lobbyists

Lobbyist Name Exclusive Duties Authorized On Withdrawn On

Lobbying Interests

Legislative Bills/Resolutions

Assembly Bill 173
Assembly Bill 173
Relating to: regulation of pharmacy benefit managers, fiduciary and disclosure requirements on pharmacy benefit managers, and application of prescription drug payments to health insurance cost-sharing requirements. (FE)

Bill Text and History

For
Notification Date
4/14/2025
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal has not yet communicated on this matter, but intends to do so at a later date.
Senate Bill 203
Senate Bill 203
Relating to: regulation of pharmacy benefit managers, fiduciary and disclosure requirements on pharmacy benefit managers, and application of prescription drug payments to health insurance cost-sharing requirements. (FE)

Bill Text and History

For
Notification Date
4/21/2025
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal has not yet communicated on this matter, but intends to do so at a later date.

Budget Bill Subjects

Health Services: Medicaid Services
Biennial budget bill treatment of matter relating to
Health Services: Medicaid Services

Notification Date
2/27/2025
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal has not yet communicated on this matter, but intends to do so at a later date.

Insurance: Departmentwide
Biennial budget bill treatment of matter relating to
Insurance: Departmentwide

Notification Date
2/27/2025
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal has not yet communicated on this matter, but intends to do so at a later date.

Insurance: Supervision of the Insurance Industry
Biennial budget bill treatment of matter relating to
Insurance: Supervision of the Insurance Industry

Notification Date
2/27/2025
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal has not yet communicated on this matter, but intends to do so at a later date.

Topics Not Yet Assigned A Bill Or Rule Number

Development, drafting or introduction of a proposal relating to the treatment of nonopioid drugs and the development of a pain management access plan
Development, drafting or introduction of a proposal relating to
Development, drafting or introduction of a proposal relating to the treatment of nonopioid drugs and the development of a pain management access plan

Action Intended To Affect
Legislative matter

Notification Date
3/12/2025
First Communication Date
3/6/2025
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal has communicated on this matter.

Development, drafting or introduction of a proposal related to sickle disease awareness month.
Development, drafting or introduction of a proposal relating to
Development, drafting or introduction of a proposal related to sickle disease awareness month.

Action Intended To Affect
Both Legislative matter and rule

Notification Date
1/13/2025
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.

Development, drafting or introduction of a proposal related to the treatment of sickle cell disease
Development, drafting or introduction of a proposal relating to
Development, drafting or introduction of a proposal related to the treatment of sickle cell disease

Action Intended To Affect
Both Legislative matter and rule

Notification Date
1/13/2025
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.

Development, drafting or introduction of a proposal Medicaid drug coverage process and procedure.
Development, drafting or introduction of a proposal relating to
Development, drafting or introduction of a proposal Medicaid drug coverage process and procedure.

Action Intended To Affect
Both Legislative matter and rule

Notification Date
1/13/2025
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.

Development, drafting or introduction of a proposal related to the creation of a rare disease advisory council.
Development, drafting or introduction of a proposal relating to
Development, drafting or introduction of a proposal related to the creation of a rare disease advisory council.

Action Intended To Affect
Both Legislative matter and rule

Notification Date
1/13/2025
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.

Development, drafting or introduction of a proposal relating to regulation of pharmaceutical manufacturers.
Development, drafting or introduction of a proposal relating to
Development, drafting or introduction of a proposal relating to regulation of pharmaceutical manufacturers.

Action Intended To Affect
Both Legislative matter and rule

Notification Date
1/13/2025
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.

Development, drafting or introduction of a proposal relating to treatment of cyclic fibrosis.
Development, drafting or introduction of a proposal relating to
Development, drafting or introduction of a proposal relating to treatment of cyclic fibrosis.

Action Intended To Affect
Both Legislative matter and rule

Notification Date
1/13/2025
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.

Total Lobbying Effort

  2025
January - June
Total
Total Lobbying Expenditures 2025
January - June
$24,000.00
Total $24,000.00
Total Hours Communicating 2025
January - June
4.50
Total 4.50
Total Hours Other 2025
January - June
38.50
Total 38.50

Percent Allocation of Lobbying Effort

Legislative Bills/Resolutions

Relating to: regulation of pharmacy benefit managers, fiduciary and disclosure requirements on pharmacy benefit managers, and application of prescription drug payments to health insurance cost-sharing requirements. (FE)
2025
January - June
2025
July - December
2026
January - June
2026
July - December
Total
2025
January - June
10%
2025
July - December
2026
January - June
2026
July - December
Total 9%

Budget Bill Subjects

2025
January - June
2025
July - December
2026
January - June
2026
July - December
Total
2025
January - June
10%
2025
July - December
2026
January - June
2026
July - December
Total 9%

Administrative Rulemaking Proceedings

No administrative rulemaking proceedings found.

Topics Not Yet Assigned A Bill Or Rule Number

2025
January - June
2025
July - December
2026
January - June
2026
July - December
Total
2025
January - June
20%
2025
July - December
2026
January - June
2026
July - December
Total 20%
2025
January - June
2025
July - December
2026
January - June
2026
July - December
Total
2025
January - June
20%
2025
July - December
2026
January - June
2026
July - December
Total 20%
2025
January - June
2025
July - December
2026
January - June
2026
July - December
Total
2025
January - June
40%
2025
July - December
2026
January - June
2026
July - December
Total 40%

Minor Efforts

No minor efforts found.

Other Matters

No other matters found.

Filed Statements of Lobbying Activity and Expenditures